◀ Back to ICAM1
CHUK — ICAM1
Text-mined interactions from Literome
Huang et al., Carcinogenesis 2004
(Neoplasm Invasiveness) :
ICAM-1 promoter activities
induced by the over-expression of wild-type NF-kappaB inducing kinase and
IkappaB kinase beta (IKKbeta) were also inhibited by both compounds
Catley et al., Br J Pharmacol 2005
(Asthma) :
Similarly,
IKK beta ( KA ) and I kappa B alpha delta N overexpression also
inhibited IL-1beta- and TNF alpha dependent increases in
ICAM-1 , IL-8 and GM-CSF in addition to IL-1beta mediated increases in cyclooxygenase-2 expression, whereas IKK alpha ( KM ) overexpression had little effect on these outputs
Uchihara et al., Int J Cancer 2006
(Hodgkin Disease) :
Coexpression of IkappaB,
IKK , NIK and TRAF dominant negative constructs with CD30
inhibited CD30 induced activation of
ICAM-1 promoter, suggesting that CD30 induces ICAM-1 via NF-kappaB signalling
Catley et al., Mol Pharmacol 2006
(Pulmonary Disease, Chronic Obstructive) :
As observed above,
ICAM-1 , IL-6, IL-8, GM-CSF, RANTES, MCP-1, GROalpha, NAP-2, and ENA-78 expression was
reduced by the
IKK inhibitors ... As observed above,
ICAM-1 , IL-6, IL-8, GM-CSF, RANTES, MCP-1, GROalpha, NAP-2, and ENA-78 expression was
reduced by the
IKK inhibitors
Mukherjee et al., J Immunol 2007
:
This study further addressed that
IkappaB kinase (IKK) , a phosphorylation dependent regulator of NF-kappaB,
plays an important regulatory role in the TNF-alpha mediated induction of the inflammatory cell surface molecule
ICAM-1